Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02042989 · ClinicalTrials.gov registry record · Phase 1

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

A Phase 1 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
68
Enrollment target
1
Study location

NCT02042989 is a Phase 1 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 68 participants, roughly in line with the 63-participant average among 10 other Advanced Cancers trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02042989, a Phase 1 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.

Conditions Studied

Advanced Cancers

Interventions

  • DRUG Vorinostat
  • DRUG MLN9708

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2014-06-27
Est. Completion 2020-01-22
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02042989

The ClinicalTrials.gov registry entry for NCT02042989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 63-participant average among 10 other Advanced Cancers trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 2 interventions - of which Vorinostat is the first listed.

NCT02042989 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02042989 about?

NCT02042989 is a clinical study titled "MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.

What is the current status of trial NCT02042989?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2014-06-27. Estimated completion is 2020-01-22.

What conditions does trial NCT02042989 study?

This clinical trial studies the following conditions: Advanced Cancers.

What interventions are being tested in trial NCT02042989?

The interventions under investigation include: Vorinostat (DRUG), MLN9708 (DRUG).

Who is sponsoring clinical trial NCT02042989?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02042989 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancers

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.